Actualités et vidéos - CRYOPORT INC. - Page 2

LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to...

Cryoport Reports First Quarter 2024 Financial Results PR Newswire NASHVILLE, Tenn., May 7, 2024 Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675 global clinical trials supported as of March 31, 2024 $242 - $252 million full year 2024 revenue guidance reiterated NASHVILLE, Tenn. , May 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in...

Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 PR Newswire NASHVILLE, Tenn., April 30, 2024 NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter...

Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire NASHVILLE, Tenn., March 12, 2024 FY 2023 revenue of $233.3 million , in-line with guidance Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% Global clinical trials supported reached a record 675 NASHVILLE, Tenn. , March 12, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies,...

Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 PR Newswire NASHVILLE, Tenn., Feb. 27, 2024 NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close. In addition to the earnings release, a...

Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services PR Newswire NASHVILLE, Tenn., Nov. 27, 2023 Companies Will Partner to Provide Complete Supply Chain Solutions for the Life Science and Biopharmaceutical Industries NASHVILLE, Tenn. , Nov. 27, 2023 /PRNewswire/ -- Cryoport Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy...

Cryoport Reports Third Quarter 2023 Financial Results PR Newswire NASHVILLE, Tenn., Nov. 8, 2023 Third quarter 2023 commercial Cell and Gene Therapy revenue up 54% year-over-year Supporting a record total of 670 clinical trials worldwide, with 81 in Phase 3 Nine months 2023 revenue of $176 million Affirms full year 2023 revenue guidance of $233 - $243 million NASHVILLE, Tenn. , Nov. 8, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of...

Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition PR Newswire NASHVILLE, Tenn., Nov. 2, 2023 Strategic Acquisition Strengthens Condition Monitoring Systems and Logistics Management Capabilities for the Biopharmaceutical Industry Throughout Cryoport's Family of Companies NASHVILLE, Tenn. , Nov. 2, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the...

Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 PR Newswire NASHVILLE, Tenn., Oct. 25, 2023 NASHVILLE, Tenn. , Oct. 25, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company will report financial results for the third quarter ended...

Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF PR Newswire NASHVILLE, Tenn., Oct. 12, 2023 NASHVILLE, Tenn. , Oct. 12, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company has signed a new three-year supply chain solutions...

Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies PR Newswire NASHVILLE, Tenn. and STEVENAGE, United Kingdom, Oct. 10, 2023 Partnership Establishes Cryoport Systems' First U.K. Logistics Center to Support Future Expansion and Provide End-to-End Supply Chain Solutions for Advanced Therapy Manufacturers NASHVILLE, Tenn. and STEVENAGE, United Kingdom , Oct. 10, 2023 /PRNewswire/ --...

Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies PR Newswire MINNEAPOLIS and NASHVILLE, Tenn., Oct. 9, 2023 Partnership will provide access to standardized and optimized apheresis collection, cryopreservation and bioprocessing processes throughout the U.S. and Europe MINNEAPOLIS and NASHVILLE , Tenn. , Oct. 9, 2023 /PRNewswire/ -- Be The Match BioTherapies ® , an organization offering solutions for companies developing and commercializing...

Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award PR Newswire NASHVILLE, Tenn., Sept. 14, 2023 Company Named "Best Cell & Gene Therapy Supplier – Cryogenic Storage" NASHVILLE, Tenn. , Sept. 14, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced...

Cryoport Reports Second Quarter 2023 Financial Results PR Newswire NASHVILLE, Tenn., Aug. 9, 2023 Second quarter revenue of $57 million , in line with previously announced preliminary results Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of 42 new trials added year-over-year Strong balance sheet with over $500 million in cash and short-term investments NASHVILLE, Tenn. , Aug. 9, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX PR Newswire NEW YORK, Aug. 4, 2023 NEW YORK , Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or the "Company") (NASDAQ: CYRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Cryoport and certain of its officers and/or...

Cryoport to Report Second Quarter 2023 Financial Results on August 9, 2023 PR Newswire NASHVILLE, Tenn., Aug. 2, 2023 NASHVILLE, Tenn. , Aug. 2, 2023 /PRNewswire/ -- Cry oport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, reproductive medicine and animal health industries, today announced that the Company will report financial results for the second quarter ended June 30, 2023...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX PR Newswire NEW YORK, July 25, 2023 NEW YORK , July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or the "Company") (NASDAQ: CYRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Cryoport and certain of its officers and/or...

LOS ANGELES, CA / ACCESSWIRE / July 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cryoport announced its financial results for the second quarter on...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX PR Newswire NEW YORK, July 18, 2023 NEW YORK , July 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or the "Company") (NASDAQ: CYRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Cryoport and certain of its officers and/or...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. (“Cryoport” or “the Company”) (NYSE: CYRX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cryoport announced its financial results for the second quarter on July 12, 2023. The Company disclosed...